Vera Therapeutics Reports $714.6 Million in Cash and Securities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy VERA?
Vera Therapeutics reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which combined with availability under its debt facility, Vera Therapeutics believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 40.790
Low
33.00
Averages
74.08
High
100.00
Current: 40.790
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share
- Financial Performance: Vera Therapeutics reported a FY GAAP EPS of -$4.66, indicating challenges in profitability that may impact investor confidence and stock performance.
- Cash Reserves: The company holds cash and cash equivalents of $714 million, which, despite the losses, provides a solid financial cushion for future R&D and operations, enhancing its survival prospects in the market.
- FDA Priority Review: Vera's atacicept has received FDA priority review for IgA nephropathy, a development that could expedite the drug's market entry and enhance the company's competitive position in the treatment landscape.
- Public Offering: Vera Therapeutics successfully priced its public offering at $42.50 per share, raising $261 million, which will support its ongoing R&D and marketing efforts, aiding the company in achieving its long-term growth objectives.
See More
Vera Therapeutics Appoints New Chief Commercial Officer
- Executive Appointment: Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer to prepare for the commercial launch of atacicept for IgA nephropathy, leveraging his extensive experience in building commercial organizations to facilitate the company's transition to a commercial-stage entity.
- Drug Potential: Atacicept, a dual BAFF/APRIL inhibitor, shows promising clinical data and the advantage of self-administration at home, with Skelton emphasizing a focus on enhancing treatment outcomes for IgAN patients, potentially transforming their quality of life.
- Clinical Trial Progress: Atacicept met its primary and key secondary endpoints in the ORIGIN Phase 2b trial, demonstrating significant reductions in proteinuria and stabilization of kidney function, which is expected to lay the groundwork for future FDA approval.
- Regulatory Advancements: The Biologics License Application (BLA) for atacicept has received Priority Review designation, with a PDUFA target action date of July 7, 2026, which, if approved, will provide new treatment options for IgAN patients and further solidify the company's market position.
See More
Vera Therapeutics Grants 344,750 Stock Options and RSUs to New Employees
- Inducement Plan Implementation: On January 5, 2026, Vera Therapeutics granted 344,750 stock options and RSUs to 18 new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Stock Option Details: Each stock option has an exercise price of $47.07, based on the closing price on the grant date, and will vest over four years, enhancing employee long-term incentives and loyalty to the company.
- Restricted Stock Units Arrangement: The RSUs will vest over four years, with the first vesting occurring on February 20, 2026, ensuring continued contributions from new employees during their service with the company.
- Strategic Company Direction: The stock options and RSUs granted reflect Vera Therapeutics' commitment to talent acquisition, aiming to drive innovation in the treatment of immunological diseases by attracting high-quality employees.
See More
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026
- Breakthrough Therapy: Vera Therapeutics' atacicept has received FDA Breakthrough Therapy Designation, and if approved, it would be the first dual-targeting B cell modulator for IgAN, significantly enhancing treatment options.
- Priority Review: The FDA has accepted the Biologics License Application (BLA) for atacicept with a target action date of July 7, 2026, indicating a strong demand for new therapies in the market.
- Clinical Trial Results: In the ORIGIN 3 trial, atacicept achieved a 46% reduction in proteinuria at 36 weeks, with statistical significance (p<0.0001) compared to placebo, providing new hope for patients.
- Self-Administration Convenience: Designed as a once-weekly subcutaneous injection, atacicept allows for at-home self-administration, enhancing treatment convenience and adherence, which could transform the treatment landscape for IgAN.
See More
Vera Therapeutics Submits IgAN Drug Application, Receives FDA Priority Review
- Regulatory Submission Success: Vera Therapeutics announced that its biologics license application for atacicept targeting IgA nephropathy received FDA priority review, with a target decision date of July 7, 2026, leading to a nearly 5% stock price increase, reflecting strong market anticipation for new therapies.
- Strong Clinical Support: The application is backed by a successful Phase 3 study that met its primary endpoint of reducing proteinuria, indicating atacicept's significant potential in treating IgAN, and if approved, it will offer patients a new self-administered treatment option.
- Intense Market Competition: Vera's competitor Otsuka has set the monthly treatment cost for a similar drug at $30,000, necessitating Vera to make strategic pricing decisions to ensure its drug's competitiveness and accessibility in the market.
- Optimistic Industry Outlook: Vera's founder and CEO Marshall Fordyce emphasized that the FDA's priority review underscores the urgent need for new therapies, and if approved, it could reshape the IgAN treatment landscape, further driving the company's growth in the biopharmaceutical sector.
See More
Vera Therapeutics Submits Kidney Drug Application, Receives FDA Priority Review
- Regulatory Submission Success: Vera Therapeutics has formally submitted its biologics license application for atacicept targeting IgA nephropathy to the FDA, receiving priority review, which marks a significant advancement in the biotech sector.
- Positive Market Reaction: The announcement led to a nearly 5% increase in Vera's stock price, reflecting strong investor confidence in the company's future potential and likely attracting further investment interest.
- Critical Timeline: The FDA has set a target action date of July 7, 2026, for the application, and if approved, Vera could quickly bring the drug to market, addressing urgent patient needs.
- Competitive Landscape Analysis: Vera's rival, Otsuka Pharmaceutical, has priced a similar medication at $30,000 per month, making Vera's pricing strategy crucial for its market performance and profitability.
See More
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share
- Financial Performance: Vera Therapeutics reported a FY GAAP EPS of -$4.66, indicating challenges in profitability that may impact investor confidence and stock performance.
- Cash Reserves: The company holds cash and cash equivalents of $714 million, which, despite the losses, provides a solid financial cushion for future R&D and operations, enhancing its survival prospects in the market.
- FDA Priority Review: Vera's atacicept has received FDA priority review for IgA nephropathy, a development that could expedite the drug's market entry and enhance the company's competitive position in the treatment landscape.
- Public Offering: Vera Therapeutics successfully priced its public offering at $42.50 per share, raising $261 million, which will support its ongoing R&D and marketing efforts, aiding the company in achieving its long-term growth objectives.
See More
Vera Therapeutics Appoints New Chief Commercial Officer
- Executive Appointment: Vera Therapeutics has appointed Matt Skelton as Chief Commercial Officer to prepare for the commercial launch of atacicept for IgA nephropathy, leveraging his extensive experience in building commercial organizations to facilitate the company's transition to a commercial-stage entity.
- Drug Potential: Atacicept, a dual BAFF/APRIL inhibitor, shows promising clinical data and the advantage of self-administration at home, with Skelton emphasizing a focus on enhancing treatment outcomes for IgAN patients, potentially transforming their quality of life.
- Clinical Trial Progress: Atacicept met its primary and key secondary endpoints in the ORIGIN Phase 2b trial, demonstrating significant reductions in proteinuria and stabilization of kidney function, which is expected to lay the groundwork for future FDA approval.
- Regulatory Advancements: The Biologics License Application (BLA) for atacicept has received Priority Review designation, with a PDUFA target action date of July 7, 2026, which, if approved, will provide new treatment options for IgAN patients and further solidify the company's market position.
See More
Vera Therapeutics Grants 344,750 Stock Options and RSUs to New Employees
- Inducement Plan Implementation: On January 5, 2026, Vera Therapeutics granted 344,750 stock options and RSUs to 18 new employees, aimed at attracting and retaining talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Stock Option Details: Each stock option has an exercise price of $47.07, based on the closing price on the grant date, and will vest over four years, enhancing employee long-term incentives and loyalty to the company.
- Restricted Stock Units Arrangement: The RSUs will vest over four years, with the first vesting occurring on February 20, 2026, ensuring continued contributions from new employees during their service with the company.
- Strategic Company Direction: The stock options and RSUs granted reflect Vera Therapeutics' commitment to talent acquisition, aiming to drive innovation in the treatment of immunological diseases by attracting high-quality employees.
See More
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026
- Breakthrough Therapy: Vera Therapeutics' atacicept has received FDA Breakthrough Therapy Designation, and if approved, it would be the first dual-targeting B cell modulator for IgAN, significantly enhancing treatment options.
- Priority Review: The FDA has accepted the Biologics License Application (BLA) for atacicept with a target action date of July 7, 2026, indicating a strong demand for new therapies in the market.
- Clinical Trial Results: In the ORIGIN 3 trial, atacicept achieved a 46% reduction in proteinuria at 36 weeks, with statistical significance (p<0.0001) compared to placebo, providing new hope for patients.
- Self-Administration Convenience: Designed as a once-weekly subcutaneous injection, atacicept allows for at-home self-administration, enhancing treatment convenience and adherence, which could transform the treatment landscape for IgAN.
See More
Vera Therapeutics Submits IgAN Drug Application, Receives FDA Priority Review
- Regulatory Submission Success: Vera Therapeutics announced that its biologics license application for atacicept targeting IgA nephropathy received FDA priority review, with a target decision date of July 7, 2026, leading to a nearly 5% stock price increase, reflecting strong market anticipation for new therapies.
- Strong Clinical Support: The application is backed by a successful Phase 3 study that met its primary endpoint of reducing proteinuria, indicating atacicept's significant potential in treating IgAN, and if approved, it will offer patients a new self-administered treatment option.
- Intense Market Competition: Vera's competitor Otsuka has set the monthly treatment cost for a similar drug at $30,000, necessitating Vera to make strategic pricing decisions to ensure its drug's competitiveness and accessibility in the market.
- Optimistic Industry Outlook: Vera's founder and CEO Marshall Fordyce emphasized that the FDA's priority review underscores the urgent need for new therapies, and if approved, it could reshape the IgAN treatment landscape, further driving the company's growth in the biopharmaceutical sector.
See More
Vera Therapeutics Submits Kidney Drug Application, Receives FDA Priority Review
- Regulatory Submission Success: Vera Therapeutics has formally submitted its biologics license application for atacicept targeting IgA nephropathy to the FDA, receiving priority review, which marks a significant advancement in the biotech sector.
- Positive Market Reaction: The announcement led to a nearly 5% increase in Vera's stock price, reflecting strong investor confidence in the company's future potential and likely attracting further investment interest.
- Critical Timeline: The FDA has set a target action date of July 7, 2026, for the application, and if approved, Vera could quickly bring the drug to market, addressing urgent patient needs.
- Competitive Landscape Analysis: Vera's rival, Otsuka Pharmaceutical, has priced a similar medication at $30,000 per month, making Vera's pricing strategy crucial for its market performance and profitability.
See More
